Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-11 am EDT
|
5-day change | 1st Jan Change | ||
| 70.70 EUR | -0.31% |
|
-2.78% | +13.30% |
| Sep. 08 | Eurofins Scientific Downgraded by Morgan Stanley |  |
| Aug. 24 | Wall Street's Three-Way Stress Test | |
| Market Cap | 12.27B 14.24B 11.62B 10.53B 19.76B 1,361B 19.86B 138B 53.08B 692B 53.5B 52.32B 2,188B | P/E 2026 * |
23.6x | P/E 2027 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise Value | 15.64B 18.15B 14.81B 13.42B 25.18B 1,734B 25.31B 176B 67.63B 882B 68.17B 66.67B 2,788B | EV / Sales 2026 * |
2.06x | EV / Sales 2027 * | 1.91x |
| Free-Float |
60.39% | Yield 2026 * |
1.13% | Yield 2027 * | 1.28% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
Xetra
| ESF0 | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
OTC Markets
| ERFSF | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript : Eurofins Scientific SE
| 1 day | -0.31% | ||
| 1 week | -2.78% | ||
| Current month | -2.54% | ||
| 1 month | +1.14% | ||
| 3 months | +9.88% | ||
| 6 months | +11.90% | ||
| Current year | +13.30% |
| 1 week | 68.38 |  | 72.36 |
| 1 month | 68.38 | | 74.78 |
| Current year | 56.84 | | 74.78 |
| 1 year | 54.86 | | 74.78 |
| 3 years | 39.47 | | 74.78 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.31% | -2.78% | +10.47% | +30.49% | 14.24B | |
| -0.71% | -6.35% | -4.87% | +9.03% | 45.48B | |
| +0.21% | -2.98% | +340.68% | +519.93% | 43.69B | |
| +1.74% | -2.24% | +37.28% | +21.57% | 43.09B | |
| +1.38% | -3.28% | +3.23% | +65.60% | 39.4B | |
| -1.44% | -5.26% | +8.78% | +36.85% | 31.91B | |
| +0.87% | -2.60% | - | - | 17.31B | |
| +0.75% | -0.64% | +18.07% | +110.32% | 16.4B | |
| +1.93% | -3.55% | +74.20% | +39.37% | 13.28B | |
| +2.18% | +2.71% | -3.31% | -33.72% | 13.05B | |
| Average | +0.66% | -2.94% | +53.84% | +88.83% | 27.78B | |
| Weighted average by Cap. | +0.49% | -3.37% | +69.33% | +115.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.58B 8.8B 7.18B 6.51B 12.21B 841B 12.27B 85.28B 32.79B 428B 33.06B 32.33B 1,352B | 8B 9.28B 7.57B 6.86B 12.88B 887B 12.94B 89.94B 34.59B 451B 34.86B 34.1B 1,426B |
| Net income | 531M 616M 503M 456M 855M 58.87B 859M 5.97B 2.3B 29.95B 2.31B 2.26B 94.64B | 660M 766M 625M 566M 1.06B 73.15B 1.07B 7.42B 2.85B 37.21B 2.88B 2.81B 118B |
| Net Debt | 3.37B 3.91B 3.19B 2.89B 5.42B 373B 5.45B 37.85B 14.56B 190B 14.67B 14.35B 600B | 3.03B 3.52B 2.87B 2.6B 4.88B 336B 4.91B 34.12B 13.12B 171B 13.22B 12.93B 541B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | €70.70 | -0.31% | 571,619 |
| 26-09-10 | €70.92 | -0.03% | 661,722 |
| 26-09-09 | €70.94 | -0.37% | 413,214 |
| 26-09-08 | €71.20 | -0.56% | 265,201 |
| 26-09-07 | €71.60 | -1.54% | 146,380 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
